Reduction of herpes simplex virus type-2 replication in cell cultures and in rodent models with peptide-conjugated morpholino oligomers.

TitleReduction of herpes simplex virus type-2 replication in cell cultures and in rodent models with peptide-conjugated morpholino oligomers.
Publication TypeJournal Article
Year of Publication2010
AuthorsEide K, Moerdyk-Schauwecker M, Stein DA, Bildfell RJ, Koelle DM, Jin L
JournalAntiviral therapy
Volume15
Issue8
Pagination1141-9
Date Published2010
ISSN2040-2058
KeywordsAcyclovir, Animals, Antiviral Agents, Cercopithecus aethiops, Disease Models, Animal, Drug Resistance, Viral, Female, Herpes Genitalis, Herpesvirus 2, Human, Immediate-Early Proteins, Mice, Mice, Inbred BALB C, Morpholines, Peptides, Recurrence, Sigmodontinae, Vero Cells, Viral Proteins, Virus Activation, Virus Replication
Abstract

Genital herpes, caused by herpes simplex virus type-2 (HSV-2), is a recurrent, lifelong disease affecting tens of millions of people in the USA alone. HSV-2 can be treated therapeutically with acyclovir (ACV) and its derivatives; however, no treatment can prevent HSV reactivation. Novel topical anti-HSV microbicides are much needed to reduce HSV-2 transmission and to treat primary or reactivated infections, especially for ACV-resistant strains. Peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs) are single-stranded DNA analogues that enter cells readily and can reduce target gene expression through steric blockage of complementary messenger RNA (mRNA).

DOI10.1111/j.1365-3164.2011.00980.x
Alternate JournalAntivir. Ther. (Lond.)